Thomas B. Smith Sells 9,593 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Stock

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) EVP Thomas B. Smith sold 9,593 shares of Collegium Pharmaceutical stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $36.62, for a total transaction of $351,295.66. Following the sale, the executive vice president now directly owns 53,816 shares of the company’s stock, valued at approximately $1,970,741.92. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Collegium Pharmaceutical Stock Performance

NASDAQ COLL opened at $38.78 on Thursday. The company has a quick ratio of 1.04, a current ratio of 1.11 and a debt-to-equity ratio of 1.71. The company has a market capitalization of $1.27 billion, a P/E ratio of 16.16 and a beta of 0.94. Collegium Pharmaceutical, Inc. has a 12-month low of $20.95 and a 12-month high of $40.95. The firm has a 50-day moving average price of $35.80 and a two-hundred day moving average price of $35.43.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its earnings results on Thursday, August 8th. The specialty pharmaceutical company reported $1.62 EPS for the quarter, beating the consensus estimate of $1.40 by $0.22. The company had revenue of $145.28 million during the quarter, compared to analysts’ expectations of $143.94 million. Collegium Pharmaceutical had a net margin of 17.32% and a return on equity of 107.62%. The business’s revenue for the quarter was up 7.2% compared to the same quarter last year. During the same period in the previous year, the company earned $1.13 EPS. Analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.82 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the stock. HC Wainwright lifted their target price on shares of Collegium Pharmaceutical from $47.00 to $50.00 and gave the stock a “buy” rating in a report on Thursday, September 5th. Truist Financial lifted their target price on shares of Collegium Pharmaceutical from $40.00 to $42.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Needham & Company LLC reaffirmed a “hold” rating on shares of Collegium Pharmaceutical in a report on Friday, August 9th. StockNews.com downgraded shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 31st. Finally, Jefferies Financial Group raised shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and boosted their price objective for the company from $41.00 to $44.00 in a report on Friday, June 7th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $42.60.

Hedge Funds Weigh In On Collegium Pharmaceutical

Hedge funds and other institutional investors have recently made changes to their positions in the company. Gladius Capital Management LP acquired a new position in shares of Collegium Pharmaceutical in the 2nd quarter valued at approximately $32,000. Principal Securities Inc. acquired a new position in shares of Collegium Pharmaceutical in the 4th quarter valued at approximately $40,000. nVerses Capital LLC raised its position in shares of Collegium Pharmaceutical by 1,600.0% in the 2nd quarter. nVerses Capital LLC now owns 1,700 shares of the specialty pharmaceutical company’s stock valued at $55,000 after buying an additional 1,600 shares in the last quarter. Assetmark Inc. raised its position in shares of Collegium Pharmaceutical by 25.5% in the 4th quarter. Assetmark Inc. now owns 5,445 shares of the specialty pharmaceutical company’s stock valued at $168,000 after buying an additional 1,108 shares in the last quarter. Finally, Sheaff Brock Investment Advisors LLC acquired a new position in shares of Collegium Pharmaceutical in the 1st quarter valued at approximately $204,000.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.